Return to homepagePandemic Pact

EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93020C00024-0-9999-1

Grant search

Key facts

  • Disease

    Ebola, Zika virus disease

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $600,000

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    MARK GEISBERG

  • Research Location

    United States of America

  • Lead Research Institution

    SILVER LAKE RESEARCH CORPORATION

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The proposal addressed the need for novel monoclonal Abs (MAbs) to characterize subsets of immune cells and cytokines in the guinea pig model. The goal is to use their novel technology to produce high-affinity MAbs against six target antigens, focusing on surface markers of immune cells, and to characterize the specificity of antibodies with guinea pig PBMCs and tissue section. These new reagents will be available to significantly enhance research capabilities for tuberculosis and other diseases such as influenza, Ebola and Zika viral infections.